US4154821A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Novel glycoproteins
Assignee: Sanofi Aventis France
•
Filing: 1978-01-23
•
Granted: 1979-05-15
•
Expires: 1998-01-23
Abstract
Abstract Novel water-soluble glycoproteins isolated from Hafnia strain having remarkable anti-inflammatory and immunostimulating activity with very good tolerance and their preparation.
Inventors
- 👤 Jean-Claude Drouet
- 👤 Marie-Odile Martin
- 👤 Dominique Biard
- 👤 Rene Zalisz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 09:45
CPC Classifications
C; C12; C12P; C12P21/00; C12P21/005; A; A61; A61P; A61P29/00; A61P31/00; A61P31/04; A61P37/00; A61P37/02; A61P37/04; C07; C07K; C07K14/00; C07K14/195; C07K14/24; C07K14/275; A61K; A61K38/00; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/822; Y10S530/00; Y10S530/806; Y10S530/82; Y10S530/825
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
22 words
A water-soluble glycoprotein extracted from the lysis of microbial bodies of Hafnia and having an apparent molecular weight of at least 300,000.
Claim 2
Dependent Claim
22 words
A water-soluble glycoprotein extracted from the lysis of microbial bodies of Hafnia and having an apparent molecular weight of at least 300,000.
Claim 3
Dependent Claim
14 words
The glycoprotein of claim 1 wherein the apparent molecular weight of at least 1,000,000.
Claim 4
Dependent Claim
40 words
The glycoprotein of claim 1 containing 40 to 50% by weight of substances with biuretogenic power, 25 to 35% by weight of neutral sugars, no diaminopimelic acid and has an ultraviolet absorption maximum at about 215 mμ and 260 mμ.
Claim 5
Dependent Claim
17 words
The glycoprotein of claim 1 wherein the Hafnia strain is No. 5731 of Pasteur Institute of Paris.
Claim 6
Dependent Claim
94 words
A process for the preparation of a glycoprotein of claim 1 comprising cultivating a Hafnia microbial strain in a solid or liquid nutritive media until complete developement of the microbial bodies, collecting the said bodies, subjecting the latter to lysis, treating the resulting lysate with at least one organic solvent, dissolving the resulting product in water and subjecting the aqueous solution to diafiltration with a porous membrane calibrate having a threshold for retaining substances with a molecular weight of at least 300,000 and subjecting the resulting solution to lyophilis to obtain the water-soluble glycoprotein.
Claim 7
Dependent Claim
22 words
The process of claim 1 wherein the lysis is an enzymatic lysis, and the lysate is treated successively with acetone and methanol.
Claim 8
Dependent Claim
12 words
The process of claim 6 wherein the enzymatic lysis effected with lysozyme.
Claim 9
Dependent Claim
18 words
The process of claim 5 wherein the Hafnia strain is No. 5731 of the Pasteur Institute of Paris.
Claim 10
Dependent Claim
20 words
Pharmaceutical composition containing an anti-inflammatorily and immunostimulating effective amount of a glycoprotein of claim 1 and an inert pharmaceutical carrier.
Claim 11
Dependent Claim
18 words
The composition of claim 9 wherein the apparent molecular weight of the glycoprotein is at least of 1,000,000.
Claim 12
Dependent Claim
40 words
The composition of claim 9 containing 40 to 50% by weight of substances with biuretogenic power, 25 to 35% by weight of neutral sugars, no diaminopimedic acid and has an ultraviolet absorption maximum at about 215 mμ and 260 mμ.
Claim 13
Dependent Claim
17 words
The composition of claim 9 wherein the Hafnia strain is No. 5731 of Pasteur Institute of Paris.
Claim 14
Dependent Claim
28 words
A method of relieving inflammation and inducing immunostimulating activity in warm-blooded animals comprising administering to warm-blooded animals an anti-inflammatorilly and immunostimulating amount of a glycoprotein of claim 1.
Claim 15
Dependent Claim
15 words
The method of claim 13 wherein the apparent molecular weight is at least of 1,000,000.
Claim 16
Dependent Claim
40 words
The method of claim 13 containing 40 to 50% by weight of substances with biuretogenic power, 25 to 35% by weight of neutral sugars, no diaminopimelic acid and has an ultraviolet absorption maximum at about 215 mμ and 260 mμ.
Claim 17
Dependent Claim
17 words
The method of claim 13 wherein the Hafnia strain is No. 5731 of Pasteur Institute of Paris.
References Cited (Backward Citations)
GB1046770A
Cited
US3616453A
Cited
US3855197A
Cited
US3716452A
Cited
US4036953A
Cited
GB1426042A
Cited
US4032663A
Cited
US3876779A
Cited
US3868303A
Cited
US3917510A
Cited
US3976544A
Cited
US4013788A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-05-14 | 1982-11-13 | 1983-05-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-05-14 | 1986-11-13 | 1987-05-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-05-14 | 1990-11-13 | 1991-05-15 | $7700.00 | Window Closed / Lapsed |